Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG To Start Drug Trial Of Xarelto In Heart Attack Prevention-Reuters


Tuesday, 13 Nov 2012 08:00am EST 

Reuters reported that Bayer AG announced that it will start the drug trial involving blood-thinner Xarelto in a bid to widen its use to become a treatment for preventing repeat heart attacks. As part of the trial with 20,000 participants, called Compass, Bayer will try to show Xarelto can complement or possibly replace Aspirin as the standard treatment for people who have suffered a heart attack due to atherosclerosis, or clogging of arteries. The Compass trial - in the third and last phase of testing required for regulatory approval. The trial will start in the first quarter of next year and should last for about five years. 

Company Quote

98.71
-2.24 -2.22%
11:35am EDT